Under a deal struck by Johnson & Johnson and the Stop TB Partnership, generic versions of J&J’s Sirturo (bedaquiline) tuberculosis treatment will be able to be supplied in low-and middle-income countries despite existing intellectual property for the brand.
J&J Faces Further Criticism Over Bedaquiline Despite Licensing Deal
Agreement With Stop TB Partnership Allows For Generic Versions Of Sirturo In LMICs
Johnson & Johnson has reached an agreement with the Stop TB Partnership that will allow generic bedaquiline versions of the firm’s Sirturo brand to be supplied in low-and middle-income countries where patents remain in effect – but critics say the deal does not go far enough.
More from Legal & IP
More from Pink Sheet
• By
Newly proposed legislation for bolstering the EU’s drug manufacturing capacity and reducing its overreliance on foreign manufacturers includes a number of measures, such a requirement for EU countries to prioritize the security of supply over price when procuring drugs.
• By
An enhanced role for patients in the European Medicines Agency was a key proposal within the EU pharmaceutical legislation overhaul – but patient groups warn this provision could be scrapped or weakened due to ongoing negotiations.
• By
The buyout excludes reviewers, but not project managers. Experts said product reviews likely would be harmed if review team-specific project managers could take the buyout.